Tari K, Satake I, Kojima S, Tsujii T, Yonese J
Dep. of Urology, Saitama Cancer Center.
Gan To Kagaku Ryoho. 1988 Sep;15(9):2719-23.
Fifteen patients with advanced renal cell carcinoma underwent chemotherapy of neocarzinostatin (NCS). First, 6-8 mg of NCS was infused into renal artery at angiography; second, 6-8 mg was infused by the same route just before ligation of renal artery at nephrectomy, if possible; and third, 2 mg was given intravenously at 2-week intervals, about 10 times. One patient who suffered from metastatic renal cancer on rs. tibia was treated by femoral arterial injection of 2 mg NCS 5 times. By treatment of NCS for advanced renal cell carcinoma 2 out of fifteen patients achieved complete regression, one patient showed partial regression and four a minor response. Effective rate (CR + PR) of NCS for metastatic renal cancer was 20%, and the response rate (CR + PR + MR) was 47%. We consider that NCS is presently the most effective drug for renal cell carcinoma.
15例晚期肾细胞癌患者接受了新制癌菌素（NCS）化疗。首先，在血管造影时将6 - 8毫克NCS注入肾动脉；其次，若可能，在肾切除术中肾动脉结扎前通过相同途径注入6 - 8毫克；第三，每2周静脉注射2毫克，共约10次。1例右胫骨发生转移性肾癌的患者通过股动脉注射NCS 2毫克，共5次进行治疗。通过NCS治疗晚期肾细胞癌，15例患者中有2例完全缓解，1例部分缓解，4例有轻微反应。NCS对转移性肾癌的有效率（完全缓解 + 部分缓解）为20%，缓解率（完全缓解 + 部分缓解 + 轻微反应）为47%。我们认为NCS目前是治疗肾细胞癌最有效的药物。
